Join
Live feed
·
PRReleasevia Quantisnow
Palatin Technologies Inc. logo

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

ByQuantisnow·Wall Street's wire, on your screen.
PTN· Palatin Technologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTN (Palatin Technologies Inc.) and more on Quantisnow.